Cumberland Pharmaceuticals
CPIX
25 hedge funds and large institutions have $3.91M invested in Cumberland Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 0 closing their positions.
670% more call options, than puts
Call options by funds: $77K | Put options by funds: $10K
19% more funds holding
Funds holding: 21 → 25 (+4)
0.55% less ownership
Funds ownership: 15.36% → 14.82% (-0.55%)
6% less capital invested
Capital invested by funds: $4.17M → $3.91M (-$265K)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$20.7K |
| 2 |
P
&Partners
Nashville,
Tennessee
|
+$20.2K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.06K |
| 4 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$1.83K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$25.3K |
| 2 |
Renaissance Technologies
New York
|
-$10.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.39K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$3K |
| 5 |
Two Sigma Advisers
New York
|
-$367 |
CPIX Hedge Fund Activity: Q4 2023 in Review
25 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q4 2023, worth a combined $3.91M — down 6.4% from $4.17M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CPIX positions and 0 closed out — a net gain of 4 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $20.7K. The largest seller was Dimensional Fund Advisors, cutting an estimated $25.3K.
- 25 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q4 2023, up from 21 in Q3 2023.
- Funds reported $3.91M of Cumberland Pharmaceuticals stock for Q4 2023, down 6.4% quarter-over-quarter.
- 4 funds opened new Cumberland Pharmaceuticals positions in Q4 2023 and 0 closed out, a net change of +4 holders.
- The largest Cumberland Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $20.7K added.
- The largest Cumberland Pharmaceuticals seller in Q4 2023 was Dimensional Fund Advisors, an estimated $25.3K sold.
Based on aggregated 13F filings for Q4 2023.